Summit Global Investments’s Ligand Pharmaceuticals LGND Stock Holding History

Summit Global Investments’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$612K	Hold	1,937	–	–	0.03%	302
2026 Q1	$387K	Sell	1,937 -480	-20%	-$95K	0.02%	377
2025 Q4	$457K	Buy	2,417 +975	+68%	+$187K	0.03%	338
2025 Q3	$255K	Buy	+1,442	New	+$214K	0.01%	419
2025 Q2	–	Sell	-10,825	Closed	-$1.14M	–	503
2025 Q1	$1.14M	Buy	10,825 +6,407	+145%	+$725K	0.08%	149
2024 Q4	$473K	Buy	+4,418	New	+$499K	0.03%	371
2024 Q2	–	Sell	-16,171	Closed	-$1.18M	–	541
2024 Q1	$1.18M	Sell	16,171 -3,226	-17%	-$238K	0.09%	182
2023 Q4	$1.39M	Sell	19,397 -2,685	-12%	-$158K	0.09%	183
2023 Q3	$1.32M	Buy	22,082 +9,845	+80%	+$648K	0.09%	170
2023 Q2	$882K	Buy	12,237 +3,837	+46%	+$288K	0.06%	256
2023 Q1	$618K	Buy	+8,400	New	+$597K	0.05%	319
2018 Q4	–	Sell	-5,450	Closed	-$933K	–	290
2018 Q3	$933K	Hold	5,450	–	–	0.13%	119
2018 Q2	$704K	Hold	5,450	–	–	0.11%	144
2018 Q1	$562K	Buy	+5,450	New	+$539K	0.09%	183

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Summit Global Investments's LGND Position: Q2 2026 in Review

Summit Global Investments held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 1,937 shares worth $612K. The position accounts for 0.03% of the portfolio, ranked #302.

Summit Global Investments first reported a position in LGND in Q1 2018 and has held it in 14 quarters since. The position peaked at $1.39M in Q4 2023. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Summit Global Investments held 1,937 shares of Ligand Pharmaceuticals worth $612K as of Q2 2026.
Summit Global Investments left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
Ligand Pharmaceuticals made up 0.03% of Summit Global Investments's portfolio in Q2 2026, its #302 holding.
Summit Global Investments first reported a position in Ligand Pharmaceuticals in Q1 2018 and has held it in 14 quarters since.
Summit Global Investments's Ligand Pharmaceuticals position peaked at $1.39M in Q4 2023.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Summit Global Investments's 13F filing for Q2 2026, filed 3 Aug 2026.